FERONSURE
FERONSURE (Recombinant human Interferon alfa – 2a, 3 M.I.U)
Therapeutic indications
Feronsure is indicated for the treatment of:
- The efficacy of interferon alfa-2a in the treatment of hepatitis C is enhanced when combined with ribavirin. Feronsureshould be given alone mainly in case of intolerance or contraindication to ribavirin.
- Hairy cell leukaemia.
- AIDS patients with progressive, asymptomatic Kaposi’s sarcoma who have a CD4 count > 250/mm3.
- Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. Feronsureis not an alternative treatment for CML patients who have an HLA-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. It is still unknown whether Feronsurecan be considered as a treatment with a curative potential in this indication.
- Cutaneous T-cell lymphoma. Interferon alfa-2a (Feronsure) may be active in patients who have progressive disease and who are refractory to, or unsuitable for, conventional therapy.
- Adult patients with histologically proven chronic hepatitis B who have markers for viral replication, i.e., those who are positive for HBV DNA or HBeAg.
- Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.
- Follicular non-Hodgkin’s lymphoma.
- Advanced renal cell carcinoma.
Patients with AJCC stage II malignant melanoma (Breslow tumourthickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.
